Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.
Lauseker, Michael
Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. [electronic resource] - Haematologica May 2012 - e14-5 p. digital
Publication Type: Letter; Comment
1592-8721
10.3324/haematol.2011.061630 doi
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Piperazines--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Pyrimidines--administration & dosage
Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. [electronic resource] - Haematologica May 2012 - e14-5 p. digital
Publication Type: Letter; Comment
1592-8721
10.3324/haematol.2011.061630 doi
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Piperazines--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Pyrimidines--administration & dosage